TIGIT Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 39.2 kDa and the accession number is Q495A1-1.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
50 μg | 在庫あり | ¥ 45,500 |
100 μg | 約5 days | ¥ 80,500 |
200 μg | 約5 days | ¥ 142,500 |
500 μg | 約5 days | ¥ 303,000 |
生物学的情報 |
1. Immobilized human CD155a-His at 10μg/mL (100μL/well) can bind human TIGIT-Fc, the EC50 of human TIGIT-Fc is 0.03-0.2μg/mL.
2.Loaded Recombinant Human TIGIT Protein, hFc Tag on ProA Biosensor, can bind Recombinant Human CD155/PVR Protein, His Tag with an affinity constant of 0.18 uM as determined in BLI assay (Routinely tested).
|
説明 | TIGIT Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 39.2 kDa and the accession number is Q495A1-1. |
Species | Human |
Expression Host | HEK293 Cells |
Tag | C-hFc |
Accession Number | Q495A1-1 |
別名 | WUCAM, VSTM3, VSIG9, T cell immunoreceptor with Ig and ITIM domains |
Construction | The Human TIGIT (NP_776160.2) (Met1-Pro141) was expressed with the Fc region of Human IgG1 at the C-terminus. |
Protein Purity |
≥ 95% as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
|
分子量 | 39.2 kDa (predicted) |
Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. |
Research Background | TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
TIGIT Protein, Human, Recombinant (hFc) WUCAM VSIG 9 VSTM 3 VSTM3 VSTM-3 VSIG9 T cell immunoreceptor with Ig and ITIM domains VSIG-9 recombinant recombinant-proteins proteins protein